Table 2.
Northern California Breast Cancer Family Registry: Characteristics of Women Diagnosed with Hormone Receptor-Positive Breast Cancer, October 1998–April 2003 (Phase II) (n=654)
| Asian American 280 (42.8) n (%)a | Hispanic 198 (30.3) n (%)a | African American 176 (26.9) n (%)a | p value | Nonuse of adjuvant hormonal therapy 144 (22.0) n (%)a | Use of adjuvant hormonal therapy 510 (78.0) n (%)a | p value | |
|---|---|---|---|---|---|---|---|
| Background characteristics | |||||||
| Age at diagnosis (mean±SD) | 49.6±8.9 | 49.7±9.3 | 51.6±9.4 | 0.055 | 50.9±9.6 | 50.0±9.1 | 0.296 |
| Year of diagnosis | |||||||
| 1998 | 6 (2.1) | 4 (2.0) | 5 (2.8) | 0.511 | 1 (0.7) | 14 (2.7) | 0.182 |
| 1999 | 27 (9.6) | 28 (14.1) | 27 (15.3) | 19 (13.2) | 63 (12.3) | ||
| 2000 | 58 (20.7) | 38 (19.2) | 33 (18.8) | 25 (17.4) | 104 (20.4) | ||
| 2001 | 66 (23.6) | 30 (15.2) | 33 (18.8) | 22 (15.3) | 107 (21.0) | ||
| 2002 | 86 (30.7) | 70 (35.4) | 56 (31.8) | 52 (36.1) | 160 (31.4) | ||
| 2003 | 37 (13.2) | 28 (14.1) | 22 (12.5) | 25 (17.4) | 62 (12.2) | ||
| Marital status | |||||||
| Single, widowed, separated, or divorced | 65 (23.2) | 79 (39.9) | 112 (63.6) | <0.001 | 49 (34.0) | 207 (40.6) | 0.154 |
| Married or living with partner | 215 (76.8) | 119 (60.1) | 64 (36.4) | 95 (66.0) | 303 (59.4) | ||
| Education levelb | |||||||
| College or higher | 170 (60.9) | 29 (14.7) | 53 (30.1) | <0.001 | 59 (41.0) | 193 (37.9) | 0.641 |
| High school diploma or equivalent | 90 (32.3) | 102 (51.5) | 108 (61.4) | 66 (45.8) | 234 (46.0) | ||
| Less than high school | 19 (6.8) | 67 (33.8) | 15 (8.5) | 19 (13.2) | 82 (16.1) | ||
| Health-related indicators and tumor characteristics | |||||||
| BMI, kg/m2 (mean±SD)b | 23.9±4.2 | 28.2±5.9 | 29.4±7.5 | <0.001 | 26.2±5.9 | 26.8±6.4 | 0.313 |
| Obese (BMI ≥30 kg/m2) | 23 (8.3) | 68 (34.3) | 63 (35.8) | <0.001 | 27 (19.0) | 127 (25.0) | 0.141 |
| ≥1 marker of increased genetic susceptibility | 106 (37.9) | 89 (45.0) | 69 (39.2) | 0.278 | 52 (36.1) | 212 (41.6) | 0.239 |
| Positive for BRCA1 or BRCA2 mutationc | 3 (1.6) | 7 (3.9) | 3 (1.9) | 0.311 | 3 (2.8) | 10 (2.4) | 0.801 |
| SEER summary stage | |||||||
| Localized | 166 (59.3) | 116 (58.6) | 108 (61.4) | 0.335 | 109 (75.7) | 281 (55.1) | <0.001 |
| Regional, direct extension or LN only | 109 (38.9) | 72 (36.4) | 63 (35.8) | 32 (22.2) | 212 (41.6) | ||
| Regional, direct extension+LN | 5 (1.8) | 10 (5.0) | 5 (2.8) | 3 (2.1) | 17 (3.3) | ||
| Histologic typeb | |||||||
| Ductal | 219 (78.5) | 154 (78.2) | 141 (81.0) | 0.183 | 105 (73.9) | 409 (80.5) | <0.001 |
| Lobular/mixed lobular | 27 (9.7) | 26 (13.2) | 23 (13.2) | 11 (7.8) | 65 (12.8) | ||
| Other specified histology | 33 (11.8) | 17 (8.6) | 10 (5.8) | 26 (18.3) | 34 (6.7) | ||
| Treatment for breast cancer | |||||||
| Surgery and radiationd | |||||||
| Mastectomy±radiation | 127 (46.2) | 92 (46.7) | 60 (34.3) | 0.073 | 66 (48.2) | 213 (41.8) | 0.015 |
| Lumpectomy+radiation | 137 (49.8) | 100 (50.8) | 109 (62.3) | 62 (45.2) | 284 (55.7) | ||
| Lumpectomy, no radiation | 11 (4.0) | 5 (2.5) | 6 (3.4) | 9 (6.6) | 13 (2.5) | ||
| Chemotherapy | 179 (63.9) | 135 (68.2) | 104 (59.1) | 0.188 | 59 (41.0) | 359 (70.4) | <0.001 |
a
Percents based on nonmissing values.
b
<1.0% missing.
c
20.2% missing.
d
1.1% missing.
Ductal, histology code 8500; lobular/mixed lobular, histolology codes 8520, 8522, 8524; other histology, all other specified histology codes.